Beam Therapeutics Stock Price Prediction

BEAM Stock  USD 26.65  1.60  6.39%   
The RSI of Beam Therapeutics' share price is above 70 as of now suggesting that the stock is becoming overbought or overvalued. The idea behind Relative Strength Index (RSI) is that it helps to track how fast people are buying or selling Beam, making its price go up or down.

Oversold Vs Overbought

72

 
Oversold
 
Overbought
The successful prediction of Beam Therapeutics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Beam Therapeutics and does not consider all of the tangible or intangible factors available from Beam Therapeutics' fundamental data. We analyze noise-free headlines and recent hype associated with Beam Therapeutics, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Beam Therapeutics' stock price prediction:
EPS Estimate Next Quarter
(1.22)
EPS Estimate Current Year
(4.72)
EPS Estimate Next Year
(4.76)
Wall Street Target Price
49.2
EPS Estimate Current Quarter
(1.16)
Using Beam Therapeutics hype-based prediction, you can estimate the value of Beam Therapeutics from the perspective of Beam Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Beam Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Beam because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Beam Therapeutics after-hype prediction price

    
  USD 26.79  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Beam Therapeutics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.
Intrinsic
Valuation
LowRealHigh
23.9935.6139.88
Details
Naive
Forecast
LowNextHigh
19.5623.8328.10
Details
18 Analysts
Consensus
LowTargetHigh
60.9767.0074.37
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-1.26-1.18-1.09
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Beam Therapeutics. Your research has to be compared to or analyzed against Beam Therapeutics' peers to derive any actionable benefits. When done correctly, Beam Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Beam Therapeutics.

Beam Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of Beam Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Beam Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Beam Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Beam Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Beam Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Beam Therapeutics' historical news coverage. Beam Therapeutics' after-hype downside and upside margins for the prediction period are 22.52 and 31.06, respectively. We have considered Beam Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
26.65
26.79
After-hype Price
31.06
Upside
Beam Therapeutics is not too volatile at this time. Analysis and calculation of next after-hype price of Beam Therapeutics is based on 3 months time horizon.

Beam Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Beam Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Beam Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Beam Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.12 
4.27
  0.14 
  0.03 
9 Events / Month
7 Events / Month
In about 9 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
26.65
26.79
0.53 
361.86  
Notes

Beam Therapeutics Hype Timeline

Beam Therapeutics is currently traded for 26.65. The entity has historical hype elasticity of 0.14, and average elasticity to hype of competition of 0.03. Beam is forecasted to increase in value after the next headline, with the price projected to jump to 26.79 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 0.53%, whereas the daily expected return is currently at 0.12%. The volatility of related hype on Beam Therapeutics is about 1629.77%, with the expected price after the next announcement by competition of 26.68. The company reported the previous year's revenue of 377.71 M. Net Loss for the year was (132.53 M) with loss before overhead, payroll, taxes, and interest of (250.67 M). Given the investment horizon of 90 days the next forecasted press release will be in about 9 days.
Check out Beam Therapeutics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.

Beam Therapeutics Related Hype Analysis

Having access to credible news sources related to Beam Therapeutics' direct competition is more important than ever and may enhance your ability to predict Beam Therapeutics' future price movements. Getting to know how Beam Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Beam Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
EDITEditas Medicine 0.26 8 per month 0.00 (0.17) 7.41 (6.42) 24.40 
CRSPCrispr Therapeutics AG 1.73 11 per month 2.51 (0.03) 4.96 (4.25) 16.95 
CRBUCaribou Biosciences(0.13)8 per month 4.67 (0.01) 7.42 (6.63) 28.53 
VERVVerve Therapeutics(0.07)9 per month 4.63 (0.01) 7.71 (9.25) 22.10 
NTLAIntellia Therapeutics(0.50)9 per month 0.00 (0.17) 5.01 (7.15) 27.28 
FATEFate Therapeutics(0.16)8 per month 0.00 (0.15) 10.63 (7.47) 22.40 
PRMEPrime Medicine, Common 0.15 9 per month 0.00 (0.07) 7.74 (9.09) 25.80 
VRTXVertex Pharmaceuticals 1.94 9 per month 0.00 (0.12) 2.30 (3.15) 9.80 
DNAGinkgo Bioworks Holdings(0.49)9 per month 0.00 (0.04) 8.95 (9.23) 27.15 
SANASana Biotechnology(0.11)10 per month 0.00 (0.27) 7.20 (8.07) 23.40 

Beam Therapeutics Additional Predictive Modules

Most predictive techniques to examine Beam price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Beam using various technical indicators. When you analyze Beam charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Beam Therapeutics Predictive Indicators

The successful prediction of Beam Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Beam Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Beam Therapeutics based on analysis of Beam Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Beam Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Beam Therapeutics's related companies.
 2023 2024 (projected)
Dividend Yield0.01190.0106
Price To Sales Ratio5.565.28

Story Coverage note for Beam Therapeutics

The number of cover stories for Beam Therapeutics depends on current market conditions and Beam Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Beam Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Beam Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Beam Therapeutics Short Properties

Beam Therapeutics' future price predictability will typically decrease when Beam Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Beam Therapeutics often depends not only on the future outlook of the potential Beam Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Beam Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding77.2 M
Cash And Short Term Investments1.2 B
When determining whether Beam Therapeutics is a strong investment it is important to analyze Beam Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Beam Therapeutics' future performance. For an informed investment choice regarding Beam Stock, refer to the following important reports:
Check out Beam Therapeutics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.58)
Revenue Per Share
4.273
Quarterly Revenue Growth
(0.17)
Return On Assets
(0.09)
Return On Equity
(0.18)
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.